Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_assertion type Assertion NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_head.
- NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_assertion description "[XRCC3 241 MetMet is an independent determinant of favorable survival in NSCLC patients treated with cisplatin/gemcitabine. A simple molecular assay to determine the XRCC3 241 genotype can be useful for customizing chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_provenance.
- NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_assertion evidence source_evidence_literature NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_provenance.
- NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_assertion SIO_000772 16407418 NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_provenance.
- NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_assertion wasDerivedFrom gad-20150221 NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_provenance.
- NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_assertion wasGeneratedBy ECO_0000203 NP66091.RAsQ7ImmXMfpoI34kfrX3aRs0tvoNcnI9K8fE-6iSy370130_provenance.